Search Result

Results for "

CB1 antagonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (1) Apoptosis (1) Arrestin (1) Autophagy (1) Bacterial (6) Cannabinoid Receptor (66) Cytochrome P450 (1) Drug Isomer (1) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (3) Environmental Pollutants (1) GPR55 (3) HIF/HIF Prolyl-Hydroxylase (2) Interleukin Related (2) Isotope-Labeled Compounds (3) mAChR (1) mTOR (1) NF-κB (1) NO Synthase (3) P-glycoprotein (1) p38 MAPK (1) PI3K (1) PPAR (1) Reference Standards (5) TNF Receptor (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (4) Infection (7) Inflammation/Immunology (7) Metabolic Disease (35) Neurological Disease (27)

By Targets:

5-HT Receptor (1)

Akt (1)

Apoptosis (1)

Arrestin (1)

Autophagy (1)

Bacterial (6)

Cannabinoid Receptor (66)

Cytochrome P450 (1)

Drug Isomer (1)

Drug Metabolite (1)

EGFR (1)

Endogenous Metabolite (3)

Environmental Pollutants (1)

GPR55 (3)

HIF/HIF Prolyl-Hydroxylase (2)

Interleukin Related (2)

Isotope-Labeled Compounds (3)

mAChR (1)

mTOR (1)

NF-κB (1)

NO Synthase (3)

P-glycoprotein (1)

p38 MAPK (1)

PI3K (1)

PPAR (1)

Reference Standards (5)

TNF Receptor (2)

By Research Areas:

Cancer (8)

Cardiovascular Disease (4)

Infection (7)

Inflammation/Immunology (7)

Metabolic Disease (35)

Neurological Disease (27)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15443

AM251 Maximum Cited Publications 23 Publications Verification	Cannabinoid Receptor	Neurological Disease
AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC₅₀ of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM .

HY-14136

Rimonabant 10+ Cited Publications SR141716	Cannabinoid Receptor Bacterial	Infection Metabolic Disease Cancer
Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a K_i of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-18697

JD-5037 5+ Cited Publications	Cannabinoid Receptor	Metabolic Disease Cancer
JD-5037 is a potent *CB₁R* antagonist with an IC₅₀ of 1.5 nM.

HY-153800

Monlunabant 1 Publications Verification (S)-MRI-1891; INV-202	Cannabinoid Receptor Arrestin	Metabolic Disease
Monlunabant ((S)-MRI-1891) is an orally active antagonist for cannabinoid receptor 1 (CB1), binds to hCB1 and hCB2 with K_i of 0.3 nM and 613 nM .

HY-14137

Rimonabant Hydrochloride 10+ Cited Publications SR 141716A Hydrochloride	Cannabinoid Receptor Bacterial	Infection Metabolic Disease Cancer
Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an K_i of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-116637

Tetrahydromagnolol Magnolignan	Cannabinoid Receptor GPR55 Drug Metabolite	Infection Neurological Disease Inflammation/Immunology
Tetrahydromagnolol (Magnolignan), the main metabolite of Magnolol, is a potent and selective cannabinoidCB2 receptor agonist (EC₅₀ =170 nM) and GPR55 antagonist. The K_i of Tetrahydromagnolol for CB2 is 416 nM, 20-fold higher than for the CB1 receptor. Magnolol shows antifungal, anti-inflammatory and analgesic effects .

HY-110125

ML-193 1 Publications Verification CID 1261822	GPR55	Neurological Disease
ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC₅₀ of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .

HY-B1161A

S-Methoprene 2 Publications Verification (+)-Methoprene; (7S)-Methoprene	Environmental Pollutants Cannabinoid Receptor	Others
S-Methoprene is an insect juvenile hormone analog and effective insecticide that blocks the transition from pupa to adult. S-Methoprene is also a CB(1) receptor ligand and inhibits the binding of the CB1 receptor antagonist [ ³H]CP-55940 to the CB1 receptor (IC₅₀: 19.31 μM) .

HY-13505

AM281 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
AM281 is a selective CB1 receptor antagonist with an IC₅₀ of 9.91 nM. AM281 inhibits CB2 receptor with an IC₅₀ of 13000 nM .

HY-10871

Otenabant 2 Publications Verification CP-945598	Cannabinoid Receptor	Metabolic Disease
Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-112340

CB1 antagonist 4	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 4 (compound 8) is a selective cannabinoid receptor 1 (CB1) inverse agonist with an IC₅₀ of 8.5 nM for human CB1. CB1 antagonist 4 shows selective for CB1 over CB2 receptors (IC₅₀ of 604.9 nM). CB1 antagonist 4 inhibits GTP binding to CB1-overexpressing cell membranes with an EC₅₀ of 18.5 nM .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (K_i=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .

HY-116649

CB1 antagonist 2 AM4113	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 2 (AM4113) is an orally active cannabinoid receptor type 1 (CB1R) antagonist. CB1 antagonist 2 suppresses appetite, reduces body weight, and blocks addictive behaviors such as heroin addiction, without causing adverse effects like nausea and depression that are associated with traditional CB1 inverse agonists. CB1 antagonist 2 can be used in studies related to obesity and opioid addiction .

HY-14791A

(±)-Ibipinabant 1 Publications Verification (±)-SLV319; (±)-BMS-646256	Cannabinoid Receptor	Metabolic Disease
(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM.

HY-14791

Ibipinabant 1 Publications Verification SLV319; BMS-646256	Cannabinoid Receptor	Metabolic Disease
Ibipinabant (SLV319) is a potent, selective and orally active antagonist of *cannabinoid CB1* receptor, with a K_i** of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K_i=7943 nM). Ibipinabant can be used for the research of obesity and diabetic .

HY-110036

GW-405833 L768242	Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB₂) agonist. GW405833 has EC₅₀ and K_i values of 0.65 nM and 3.92 nM for CB₂, and EC₅₀ and K_i values of 16.1 μM and 4772 nM for *CB₁. GW-405833 also exhibits non-competitive CB₁* antagonist, exerting its analgesic and and anti-inflammatory effect through a *CB₁* receptor (rather than CB₂) dependent mechanism. GW-405833 can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .

HY-10013A

Taranabant racemate MK-0364 racemate	Cannabinoid Receptor	Neurological Disease
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor extracted from patent WO 2004048317 A1 .

HY-130311

2-Linoleoyl glycerol 2-Monolinolein; 2-Monolinoleoylglycerol	Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol (2-Monolinolein) is a partial CB1 receptor agonist with a pEC₅₀ of 4.781. 2-Linoleoyl glycerol activates the hCB1 receptor. 2-Linoleoyl glycerol does not induce an increase in intracellular free Ca ²⁺. 2-Linoleoyl glycerol can be used in the research of neurological disorders .

HY-117139

NESS 0327 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
NESS 0327 is a cannabinoid antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor .

HY-122964

URB447	Cannabinoid Receptor	Metabolic Disease
URB447 is a peripherally restricted *CB₁* cannabinoid antagonist (IC₅₀: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB₁-dependent responses. URB447 can be used for research of obesity .

HY-103335

O1918 1 Publications Verification	Cannabinoid Receptor	Cardiovascular Disease
O1918 is a selective non-CB₁ receptor and GPR18 antagonist.

HY-12790

CB1-IN-1 BPRCB1184	Cannabinoid Receptor	Neurological Disease
CB1-IN-1 (BPRCB1184) is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR	Metabolic Disease Cancer
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .

HY-141411A

Zevaquenabant (S)-MRI-1867	Cannabinoid Receptor NO Synthase	Metabolic Disease
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .

HY-146134

PGN36	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with K_is of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD) .

HY-14136S

Rimonabant-d10 SR141716-d₁₀	Isotope-Labeled Compounds Cannabinoid Receptor Bacterial	Infection Metabolic Disease Cancer
Rimonabant-d₁₀ is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-14788

Drinabant AVE1625	Cannabinoid Receptor	Metabolic Disease
Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC₅₀ values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R .

HY-103327

MJ15	Cannabinoid Receptor	Metabolic Disease
MJ15 is a potent and selective CB1 receptor antagonist with a K_i of 27.2 pM and an IC₅₀ of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice .

HY-10871A

Otenabant Hydrochloride CP 945598 Hydrochloride	Cannabinoid Receptor	Metabolic Disease
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-110036A

GW405833 hydrochloride L768242 hydrochloride	Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GW405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB₂) agonist. GW405833 has EC₅₀ and K_i values of 0.65 nM and 3.92 nM for CB₂, and EC₅₀ and K_i values of 16.1 μM and 4772 nM for *CB₁. GW405833 hydrochloride also exhibits non-competitive CB₁* antagonist, exerting its analgesic effect through a *CB₁* receptor (rather than CB₂) dependent mechanism. GW405833 hydrochloride can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 hydrochloride inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .

HY-152581

*CB2R antagonist* 3**	Cannabinoid Receptor	Inflammation/Immunology
CB2R antagonist 3 is a selective antagonist of cannabinoid type 2 receptor (CB2R). CB2R antagonist 3 has high affinity for human CB2R and specific selectivity for CB1R. CB2R antagonist 3 can be combined with CB65 (HY-110047), the activator of CB2R. CB2R antagonist 3 effectively up-regulates the expression of anti-inflammatory cytokines and down-regulates the expression of pro-inflammatory cytokines .

HY-14753

Rosonabant	Cannabinoid Receptor	Cardiovascular Disease Metabolic Disease
Rosonabant is a selective antagonist for cannabinoid receptor (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder .

HY-14137S

Rimonabant-d10 hydrochloride	Isotope-Labeled Compounds Cannabinoid Receptor Bacterial	Infection Metabolic Disease Cancer
Rimonabant-d₁₀ (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an K_i of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3) .

HY-110194

Virodhamine TFA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-133533

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity *cannabinoid CB₁* receptor** antagonist with a K_i of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice .

HY-178857

CB1 antagonist 6	Cannabinoid Receptor	Metabolic Disease
CB1 antagonist 6 (Compound 11jE2) is an orally active *CB1R* antagonist, with an IC₅₀ value of 23 nM. CB1 antagonist 6 significantly reduces food intake and body weight, improves glucose tolerance and insulin resistance, and decreases serum ALT and AST levels in diet-induced obese (DIO) mice, demonstrating hepatoprotective effects. CB1 antagonist 6 can be used for the study of metabolic syndrome (obesity, diabetes) .

HY-12606

BMS-812204	Cannabinoid Receptor	Metabolic Disease
BMS-812204 is a highly selective CB-1 receptor antagonist. BMS-812204 is promising for research of obesity and metabolic disorders .

HY-N6097

Amauromine	Cannabinoid Receptor	Neurological Disease
Amauromine is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist with K_i and K_b values of 178 nM and 66.6 nM, respectively .

HY-174335

UVI3502	Cannabinoid Receptor	Neurological Disease
UVI3502 is a cannabinoid receptor 1 (CB1) antagonist with an IC₅₀ value of 4641 nM for CB1 and approximately 16200 nM for CB2. UVI3502 blocks G_i/o protein coupling induced by the agonist CP55,940. UVI3502 is promising for research of endocannabinoid system-related diseases in the central nervous system (such as cognitive impairment and neurodegenerative diseases) .

HY-110179

PSNCBAM-1	Cannabinoid Receptor	Metabolic Disease
PSNCBAM-1 is a selective CB1 receptor allosteric antagonist with an EC₅₀ of 0.1 μM. PSNCBAM-1 can be used in the researches of obesity .

HY-121827

LH21 1 Publications Verification	Cannabinoid Receptor	Metabolic Disease
LH-21 is a potent in vivo neutral cannabinoid **CB1 receptor** antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .

HY-W011040

LY320135	Cannabinoid Receptor 5-HT Receptor mAChR	Neurological Disease
LY320135 is a potent and selective antagonist of *CB1* receptor, with a K_i of 141 nM. LY320135 also binds to 5-HT₂ and muscarinic receptors with K_is of 6.4 μM and 2.1 μM, respectively. LY320135 exhibits neuroprotective effect .

HY-103336

Tocrifluor 1117 T1117	GPR55 Cannabinoid Receptor	Cardiovascular Disease
Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid *CB1* receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm) .

HY-120653

CB1 antagonist 5	Cannabinoid Receptor	Neurological Disease
CB1 antagonist 5 (Compound 25) is an antagonist for CB1 cannabinoid receptor, with a K_i of 243 nM and an EC₅₀ of 195 nM .

HY-U00397

CB1 antagonist 1	Cannabinoid Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
CB1 antagonist 1 is an antagonist of CB1 receptor, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.

HY-169820

CE-178253 benzenesulfonate	Cannabinoid Receptor	Neurological Disease
CE-178253 benzenesulfonate is a *CB1* antagonist with central nervous system activity.

HY-W770198

2-Linoleoyl glycerol-d5 2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅	Isotope-Labeled Compounds Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

HY-141411

(Rac)-Zevaquenabant (Rac)-MRI-1867	Cannabinoid Receptor NO Synthase	Others
(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB₁R)/iNOS antagonist, with a K_i of 5.7 nM for CB₁R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis .

HY-103326

NIDA-41020	Cannabinoid Receptor	Neurological Disease
NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a K_i of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET) .

HY-121616

(R)-SLV 319	Cannabinoid Receptor	Neurological Disease
(R)-SLV 319 is a potent and selective cannabinoid receptor 1 (CB1) antagonist with a K_i value of 894 nM. (R)-SLV 319 is a dextrorotatory counterpart of SLV 319

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-116637

Tetrahydromagnolol Magnolignan	Classification of Application Fields Magnoliaceae Phenols Polyphenols Magnolia Liliflora Desr. Plants Inflammation/Immunology Disease Research Fields Source Classification	Cannabinoid Receptor GPR55 Drug Metabolite
Tetrahydromagnolol (Magnolignan), the main metabolite of Magnolol, is a potent and selective cannabinoidCB2 receptor agonist (EC₅₀ =170 nM) and GPR55 antagonist. The K_i of Tetrahydromagnolol for CB2 is 416 nM, 20-fold higher than for the CB1 receptor. Magnolol shows antifungal, anti-inflammatory and analgesic effects .

HY-N6932

Voacamine	Alkaloids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Indole Alkaloids Source Classification	Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR
Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .

HY-N6097

Amauromine	Alkaloids Microorganisms Indole Alkaloids Source Classification	Cannabinoid Receptor
Amauromine is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist with K_i and K_b values of 178 nM and 66.6 nM, respectively .

Cat. No.	Product Name	Chemical Structure

HY-14136S

Rimonabant-d10
Rimonabant-d₁₀ is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-14137S

Rimonabant-d10 hydrochloride
Rimonabant-d₁₀ (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an K_i of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3) .

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CB1 antagonists

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products